18.07.2012 • News

DSM, Recepta Announce Contract Manufacturing Agreement

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced that it has signed a biologics contract manufacturing agreement with its first Brazilian client, Recepta Biopharma in São Paulo.

The contract covers the process development and cGMP manufacture by DSM of one of Recepta's lead antibodies at its facilities based in Groningen, The Netherlands. DSM started production to supply drug substance materials to be used in the initial clinical trials of this antibody beginning in May of 2012.

This project represents DSM Biologics first agreement in the high growth South American market place. Recepta Biopharma is a biotechnology company dedicated to the research and development of monoclonal antibodies to be used in the treatment of cancer.

In addition to the R&D and manufacturing site in Groningen, DSM is building operations in Brisbane, Australia, with the governments of Queensland and the Commonwealth.

Financial terms were not disclosed.

 

 

 

 

 

 

 

 

 

 

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.